IGF-II R

IGF-II R

IGF-II R Overview

Molecule Name
Insulin-like growth factor II receptor
Synonyms
Cation-independent mannose-6-phosphate receptor,CI Man-6-P receptor,CI-MPR,M6PR,300 kDa mannose 6-phosphate receptor (MPR 300),Insulin-like growth factor 2 receptor,Insulin-like growth factor II receptor (IGF-II receptor),M6P/IGF2 receptor (M6P/IGF2R),CD2
Drug Development Progress
Drugs in Clinical Trials0
Approved Drugs1
Highest Development StageApproved
Target Synonym
Insulin-like growth factor 2 receptor,IGF-II receptor,CD222,Insulin Like Growth Factor 2 Receptor,M6P/IGF2R,M6P/IGF2 receptor,CI Man-6-P receptor,Insulin-like growth factor II receptor,IGF2R,300 KDa Mannose 6-Phosphate Receptor,MPR 300,MPRI,Cation-Independent Mannose-6-Phosphate Receptor,Cation-Independent Mannose-6 Phosphate Receptor,CD222 Antigen,CI-M6PR,MPR300,CI-MPR,CIMPR,M6P-R,MPR1,M6PR,Receptor, IGF Type 2
Background
IGF2R, also known as the cation-independent mannose-6-phosphate receptor, is found ubiquitously in human tissues with a truncated soluble form of the receptor present in the circulation. Full-length, 300-kDa, IGF2R comprises a large N-terminal extracellular region of 15 homologous domains, a single membrane-spanning region and a small cytoplasmic tail. In addition to IGF-II binding, major IGF2R functions include sorting newly synthesized lysosomal enzymes and endocytosis of extracellular lysosomal enzymes. To perform these disparate functions, the extracellular region contains binding sites for IGF-II and phosphomannosyl residues

IGF-II R Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Avalglucosidase alfaneoGAA; GZ-402666; Neo-rhGAA; NeoGAAApprovedGenzyme CorpNexviazyme, Nexviadyme, 耐而赞United StatesGlycogen Storage Disease Type IIGenzyme Corp2021-08-06
Glycogen Storage Disease Type II
Details